Sergej Erschow

Sergej Erschow

Auto-generated profile, based on publicly available information

Sergej Erschow

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2026 in European Heart Journal
Verified
Journal Article
Open access
MJMira Jung
Mira Jung
ASArne Schmidt
Arne Schmidt
MSMarida Sansonetti
Marida Sansonetti
BSBashar Al Soodi
Bashar Al Soodi
STSabrina Thum
Sabrina Thum
Thomas ThumThomas Thum
Thomas Thum
Background and Aims: Cardiac remodelling following MI is intricately linked to macrophage polarization dynamics, yet the underlying mechanisms remain incompletely elucidated. In this study, circHIPK2, a novel circRNA, was identified as being upregulated in inflammatory cardiac macrophages following MI. Its expression correlated with post-MI inflammation dynamics, suggesting a regulatory role in macrophage polarization. It was hypothesized that circHIPK2 functions as a molecular switch of macrophage polarization during MI progression. Methods: To test this hypothesis, circHIPK2 levels were modulated in vitro using siRNA and overexpression vectors. A murine MI model with macrophage-targeted inhibition of circHIPK2 through AAV9-mediated shRNA delivery was employed. Cardiac function was evaluated using echocardiography, histology, and PET imaging. An ex vivo co-culture platform incorporating living myocardial slices from heart failure patients and circHIPK2-modulated human iPSC-derived macrophages was established to explore a translational potential. Results: CircHIPK2 interacts with its binding partner G3BP1 to promote stress granule formation in macrophages. This interaction initiates a downstream inflammatory cascade, highlighting its role in immune regulation. Inhibition of circHIPK2 suppressed inflammatory signalling and reduced pro-inflammatory cytokine secretion. In a mouse model of MI, macrophage-specific inhibition of circHIPK2 improved cardiac function, reshaped the inflammatory environment, and attenuated fibrosis progression. Silencing circHIPK2 in human macrophages demonstrated therapeutic potential in established heart failure, promoting beneficial cardiac healing. Conclusions: Targeting circHIPK2 in macrophages may represent a promising therapeutic strategy for treating inflammatory cardiac conditions and heart failure, potentially leading to the development of RNA-based therapies targeting immune cells in MI treatment.

24 April 2026 in Circulation Research
Verified
Journal Article
Open access
NFNatali Froese
Natali Froese
ISIvanna Shymotiuk
Ivanna Shymotiuk
AFAlexander Froese
Alexander Froese
FPFelix Polten
Felix Polten
JJJonas Jablinski
Jonas Jablinski
CRChristian Riehle
Christian Riehle
BACKGROUND: Cardiomyocyte mitochondria align with sarcomeres during heart development. Mitochondrial motility is controlled by RHOT (ras homolog family member T) 1 and RHOT2. RHOT1 and RHOT2 are atypical Rho-like small GTPases that are anchored to the outer mitochondrial membrane and couple mitochondria to kinesin and dynein motors. We hypothesized that RHOT protein expression and mitochondrial motility are required for mitochondrial positioning during cardiomyocyte development. METHODS: We generated mice with cardiomyocyte-selective deletion of Rhot1 and Rhot2 during embryogenesis (cRhot1/2-KO [constitutive and embryonic cardiomyocyte-selective Rhot1 /2 knockout]) or tamoxifen-inducible deletion in the adult heart (iRhot1/2-KO [inducible cardiomyocyte-selective Rhot1/2 knockout]) to assess the importance of mitochondrial motility during and after cardiomyocyte maturation. Mitochondrial motility was determined by a motor protein–driven single mitochondria motility assay. Respiratory capacity was measured in isolated mitochondria. Intracellular mitochondrial localization and ATP production in isolated cardiomyocytes were assessed by confocal microscopy and after adenoviral expression of the fluorescence resonance energy transfer–based ATP biosensor ATeam. Cardiac ultrastructure was assessed by electron micrographs; mass spectrometry was used for proteome analysis. RESULTS: cRhot1/2-KO mice developed fatal cardiomyopathy associated with sarcomere disarray and perinuclear accumulation of mitochondria and ATP production. Mitochondria isolated from cRhot1/2-KO hearts exhibited impaired motility but preserved respiratory capacity. Mechanistically, proteome analysis identified that RHOT proteins bind mitochondria to contractile muscle fiber proteins. In contrast, inducible deletion of Rhot1 and Rhot2 in adult iRhot1/2-KO mice did not result in heart failure. Despite impaired motility of isolated mitochondria, intracellular mitochondrial localization, local ATP production, and sarcomere structure were preserved in adult iRhot1/2-KO hearts after cardiomyocyte maturation. CONCLUSIONS: RHOT proteins bind mitochondria to contractile muscle fiber proteins and are required for mitochondrial positioning in cardiomyocytes during development. Our study links mitochondrial motility and local ATP production to structural and functional maturation of the heart.

21 January 2026 in European Journal of Heart Failure
Verified
Journal Article
Open access
TPTobias J Pfeffer
Tobias J Pfeffer
FMFaramarz Matinmehr
Faramarz Matinmehr
ARAnte Radocaj
Ante Radocaj
SHSusanna Haidari
Susanna Haidari
LELukas Eisen
Lukas Eisen
MRMelanie Ricke-Hoch
Melanie Ricke-Hoch
Aims: Peripartum cardiomyopathy (PPCM) is characterized by left-ventricular systolic dysfunction. Plasminogen-activator-inhibitor 1 (PAI-1) and 16K-prolactin (PRL) are known drivers of PPCM. Treatment of cardiogenic shock (CS) complicating PPCM is challenging. The calcium sensitizer levosimendan (LS) is considered as a beneficial therapy in CS. There are only sparse data regarding the safety and efficacy of LS-treatment in PPCM. We aimed to investigate the molecular effects and safety of LS-treatment in the PPCM mouse model (cardiomyocyte-specific-knockout of signal-transducer-and-activator-of-transcription 3 (STAT3), CKO) and in patients from the German PPCM registry. Methods and results: In the PPCM mouse model, LS-treatment aggravated postpartum heart failure associated with fibrosis, reduced capillary density, and enhanced mortality, whereas LS-treatment together with the PRL-inhibitor bromocriptine (BR) preserved cardiac function. In CKO hearts, LS induced PAI-1 expression via the upregulation of thrombospondin-1/-4, transforming-growth-factor-β, and activation of SMAD2 that could be prevented by combination with BR. In the German PPCM registry, 17 PPCM patients with CS were treated with LS and BR. Despite the severity of CS, all these patients survived the acute phase, and most patients showed cardiac recovery in the ensuing course of the disease (left ventricular ejection fraction at 3-month follow-up: 40 ± 19%). Conclusion: Thus, the combination therapy with LS and BR seems to be a safe and potentially beneficial therapeutic concept for the treatment of PPCM patients with CS. As experimental PPCM mouse data suggest that treatment of PPCM patients in CS with LS alone may worsen cardiac function by enhancing the PRL/PAI-1-dependent pathomechanism, treatment of LS in PPCM patients should always be accompanied by BR treatment.

17 June 2026 in Journal of Translational Medicine
Verified
Journal Article
Open access
FMFranziska E. Müller
Franziska E. Müller
FBFrauke S. Bahr
Frauke S. Bahr
SESergej Erschow
Sergej Erschow
MKMartina Kasten
Martina Kasten
MHMaren Heimerl
Maren Heimerl
MRMelanie Ricke-Hoch
Melanie Ricke-Hoch
Background: Myocardial infarction (MI) is among the leading causes of death worldwide, and a precisely regulated inflammatory response is essential for effective cardiac repair and long-term outcome. The serotonergic system regulates immune cell functions, yet its contribution to post-MI remodeling is incompletely understood. Methods: Here, we investigated the role of serotonin receptor 7 (5-HT7R) in post-infarction inflammation and outcome after permanent left anterior coronary artery ligation in mice, and complementary analysis of peripheral blood mononuclear cells (PBMCs) obtained from patients with acute MI. Results: Three days after MI, 5-HT7R mRNA expression was significantly upregulated in the infarct region compared to remote myocardium and sham operated mice. RNA-sequencing of isolated murine CD11b + cells demonstrated high 5-HT7R expression in cardiac macrophages during the acute phase, which was confirmed by immunohistochemistry. Systemic 5-HT7R-knockout did not affect basal cardiac function but resulted in impaired left ventricular function and enhanced inflammatory signatures 14 days after MI without changes in infarct size. Pharmacological activation of 5-HT7R signaling with the selective agonist LP-211 increased survival after MI, although global systolic function among survivors was not improved. Transcriptomic profiling of cardiac macrophages 3 days after MI revealed bidirectional regulation of inflammatory and metabolic programs depending on 5-HT7R activity, including altered expression of Got1 and S100A9 . Complementary, in PBMCs from MI patients Got1 expression was reduced, while S100A9 was increased, and both correlated with 5-HT7R expression. Conclusions: These data suggest 5-HT7R as a regulator of post-MI immune responses and a potential target to improve repair and survival.